This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Shultz DB, Filippi AR, Thariat J, Mornex F, Loo BW, Jr., Ricardi U. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol 2014; 9: 1426-33. doi:10.1097/JTO.0000000000000317ShultzDBFilippiARThariatJMornexFLooBWRicardiUStereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancerJ Thorac Oncol2014914263310.1097/JTO.0000000000000317Open DOISearch in Google Scholar
Shah JL, Loo BW, Jr. Stereotactic ablative radiotherapy for early-stage lung cancer. Semin Radiat Oncol 2017; 27: 218-28. doi: 10.1016/j.semradonc.2017.03.001ShahJLLooBWStereotactic ablative radiotherapy for early-stage lung cancerSemin Radiat Oncol2017272182810.1016/j.semradonc.2017.03.001Open DOISearch in Google Scholar
Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70: 685-92. doi: 10.1016/j.ijrobp.2007.10.053LagerwaardFJHaasbeekCJSmitEFSlotmanBJSenanSOutcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancerInt J Radiat Oncol Biol Phys2008706859210.1016/j.ijrobp.2007.10.053Open DOISearch in Google Scholar
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-6. doi: 10.1001/jama.2010.261TimmermanRPaulusRGalvinJMichalskiJStraubeWBradleyJet alStereotactic body radiation therapy for inoperable early stage lung cancerJAMA20103031070610.1001/jama.2010.261Open DOISearch in Google Scholar
Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101: 1623-31. doi: 10.1002/cncr.20539OnishiHArakiTShiratoHNagataYHiraokaMGomiKet alStereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional studyCancer200410116233110.1002/cncr.20539Open DOISearch in Google Scholar
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24: 4833-9. doi: 10.1200/JCO.2006.07.5937TimmermanRMcGarryRYiannoutsosCPapiezLTudorKDeLucaJet alExcessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancerJ Clin Oncol2006244833910.1200/JCO.2006.07.5937Open DOISearch in Google Scholar
Tekatli H, Haasbeek N, Dahele M, De Haan, Verbakel PW, Bongers E, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “ultracentral” non-small cell lung cancer. J Thorac Oncol 2016; 11: 1081-9. doi: 10.1016/j.jtho.2016.03.008TekatliHHaasbeekNDaheleMDeHaanVerbakelPWBongersEet alOutcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “ultracentral” non-small cell lung cancerJ Thorac Oncol2016111081910.1016/j.jtho.2016.03.008Open DOISearch in Google Scholar
Haseltine JM, Rimner A, Gelblum DY, Modh A, Rosenzweig KE, Jackson A, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 2016; 6: e27-33. doi: 10.1016/j.prro.2015.09.012HaseltineJMRimnerAGelblumDYModhARosenzweigKEJacksonAet alFatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial treePract Radiat Oncol20166e273310.1016/j.prro.2015.09.012Open DOISearch in Google Scholar
Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryanet WF, al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol 2019; 37: 1316-25. doi: 10.1200/JCO.18.00622BezjakAPaulusRGasparLETimmermanRDStraubeWLRyanetWFSafety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 TrialJ Clin Oncol20193713162510.1200/JCO.18.00622Open DOISearch in Google Scholar
Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eyben R, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer 2015; 89: 50-6. doi: 10.1016/j.lungcan.2015.04.014ChaudhuriAATangCBinkleyMSJinMWynneJFvon EybenRet alStereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumorsLung Cancer20158950610.1016/j.lungcan.2015.04.014Open DOISearch in Google Scholar
Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys 2014; 88: 1120-8. doi: 10.1016/j.ijrobp.2014.01.022ChangJYLiQQXuQYAllenPKRebuenoNGomezDRet alStereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”Int J Radiat Oncol Biol Phys2014881120810.1016/j.ijrobp.2014.01.022Open DOISearch in Google Scholar
Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011; 6: 2036-43. 12. doi: 10.1097/JTO.0b013e31822e71d8HaasbeekCJLagerwaardFJSlotmanBJSenanSOutcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancerJ Thorac Oncol201162036431210.1097/JTO.0b013e31822e71d8Open DOISearch in Google Scholar
Raman S, Yau V, Pineda S, Le LW, Lau A, Bezjak A, et al. Ultracentral tumors treated with stereotactic body radiotherapy: single-institution experience. Clin Lung Cancer 2018; 19: e803-e810. doi: 10.1016/j.cllc.2018.06.001RamanSYauVPinedaSLeLWLauABezjakAet alUltracentral tumors treated with stereotactic body radiotherapy: single-institution experienceClin Lung Cancer201819e803e81010.1016/j.cllc.2018.06.001Open DOISearch in Google Scholar
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88: 20150036. doi: 10.1259/bjr.20150036AdebahrSColletteSShashELambrechtMLe PechouxCFaivre-FinnCet alLungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveBr J Radiol2015882015003610.1259/bjr.20150036Open DOISearch in Google Scholar
Giuliani M, Mathew AS, Bahig H, Bratman SV, Filion E, Glicket D, et al. SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer - a safety and efficacy trial. Clin Lung Cancer 2018; 19: e529-32. doi: 10.1016/j.cllc.2018.04.001GiulianiMMathewASBahigHBratmanSVFilionEGlicketDet alSUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer - a safety and efficacy trialClin Lung Cancer201819e5293210.1016/j.cllc.2018.04.001Open DOISearch in Google Scholar
Matsuo Y. A systematic literature review on salvage radiotherapy for local or regional recurrence after previous stereotactic body radiotherapy for lung cancer. Technol Cancer Res Treat 2018; 17: 1533033818798633. doi: 10.1177/1533033818798633MatsuoYA systematic literature review on salvage radiotherapy for local or regional recurrence after previous stereotactic body radiotherapy for lung cancerTechnol Cancer Res Treat201817153303381879863310.1177/1533033818798633Open DOISearch in Google Scholar
Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, et al. Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 2011; 101: 260-6. doi: 10.1016/j.radonc.2011.09.012PeulenHKarlssonKLindbergKTullgrenOBaumannPLaxIet alToxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapyRadiother Oncol2011101260610.1016/j.radonc.2011.09.012Open DOISearch in Google Scholar
Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, et al. Long-term outcomes of salvage stereotactic ablative radiotherapy for isolated lung recurrence of non-small cell lung cancer: a phase II clinical trial. J Thorac Oncol 2017; 12: 983-92. doi: 10.1016/j.jtho.2017.02.018SunBBrooksEDKomakiRLiaoZJeterMMcAleerMet alLong-term outcomes of salvage stereotactic ablative radiotherapy for isolated lung recurrence of non-small cell lung cancer: a phase II clinical trialJ Thorac Oncol2017129839210.1016/j.jtho.2017.02.018Open DOISearch in Google Scholar
Binkley MS, Hiniker SM, Chaudhuri A, Maxim PG, Diehn M, Loo BW Jr, et al. Dosimetric factors and toxicity in highly conformal thoracic reirradiation. Int J Radiat Oncol Biol Phys 2016; 94: 808-15. doi: 10.1016/j.ijrobp.2015.12.007BinkleyMSHinikerSMChaudhuriAMaximPGDiehnMLooBW Jret alDosimetric factors and toxicity in highly conformal thoracic reirradiationInt J Radiat Oncol Biol Phys2016948081510.1016/j.ijrobp.2015.12.007Open DOISearch in Google Scholar
Shultz DB, Trakul N, Maxim PG, Diehn M, Loo BW, Jr. Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. Pract Radiat Oncol 2014; 4: 272-8. doi: 10.1016/j.prro.2013.08.005ShultzDBTrakulNMaximPGDiehnMLooBWVagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chestPract Radiat Oncol20144272810.1016/j.prro.2013.08.005Open DOISearch in Google Scholar
